Prebiotics, Gut Microbiota, and Cardiometabolic Health

NCT ID: NCT02346838

Last Updated: 2024-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Forty-eight prediabetic men and women (50-75 years of age) will participate in a 6-week feeding study in which they will randomized to receive either 10 g/day of inulin or placebo. All subjects will be fed an isocaloric diet (50% carbohydrate, 35% fat, 15% protein,) controlled for micronutrient content for 6 weeks to avoid the potential confound of individual differences in diet on gut microbiota. Measurements of intestinal permeability, insulin sensitivity, and skeletal muscle metabolic flexibility will be made prior to and following the controlled feeding period. Stool samples will be collected to assess gut microbial communities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prebiotics have been defined as "selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring health benefit(s) upon host health". Commonly used prebiotics are inulin-type fructans, fructo-oligosaccharides, xylo-oligosaccharides and galacto-oligosaccharides and while all prebiotics are fibers, not all fibers are prebiotics. The proliferation of a targeted bacterial species, in particular, Bifiodobacterium spp. and Lactobacillus spp. contribute to host cardiometabolic health in many ways including, but not limited to, short chain fatty acid production and, modulation of gut barrier function, endotoxin concentrations, inflammatory pathways, and energy metabolism however, to our knowledge the potential benefits of prebiotic supplementation on cardiometabolic dysfunction has received little attention. Although the concept that dysbiosis of the gut microbiota leads to metabolic endotoxemia and increased risk of cardiometabolic disease is novel, very little information is available in humans. The significance of our proposal includes providing proof of concept efficacy of prebiotic supplementation with inulin on cardiometabolic dysfunction and assessing its relation with changes in gut bacterial communities, intestinal permeability, and metabolic endotoxemia in prediabetes, a condition affecting a substantial segment of the population. Our study could lead to the identification of prebiotic supplementation with inulin as a simple and efficacious strategy for reducing cardiometabolic risk in prediabetes which could change clinical practice by informing dietary recommendations and increasing acceptance of prebiotics by the scientific and medical community.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prediabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inulin

Participants will receive 10 g of inulin powder each day for 6 weeks.

Group Type EXPERIMENTAL

Inulin

Intervention Type DIETARY_SUPPLEMENT

The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.

Placebo

Participants will receive 10 g of maltodextrin each day for 6 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inulin

The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.

Intervention Type DIETARY_SUPPLEMENT

Placebo

The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prebiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women; postmenopausal women not taking hormone replacement therapy.
* Fasting glucose between 5.6 - 6.9 mmol/L and/or a 2h plasma glucose between 7.8-11.1 mmol/L following a 75 g oral glucose tolerance test.
* Weight stable for previous 6 months (+/- 2.0 kg).
* Sedentary to recreationally active
* Willing to be randomized to treatment or placebo.
* Verbal and written informed consent.
* No plans to gain/lose weight or change physical activity level.
* Willing to pick up food daily, and consume foods provided for the 6-week controlled feeding period.

Exclusion Criteria

* BMI less than 25 kg/m2 or greater than 40 kg/m2 or body mass greater than 300 pounds due to limit of DEXA.
* Diabetes or diabetes medications
* Prebiotic or probiotic supplement or product consumption in prior 3 months.
* Total cholesterol \> 6.2 mmol/L; triglycerides \> 4.5 mmol/L.
* Blood pressure \> 140/90 mmHg or antihypertensive medications.
* Diagnosed inflammatory disease (e.g. lupus, irritable bowel, periodontal disease, etc)
* Fructo, galacto-, xylo-oligosaccharide intake \> 3 g/day.
* Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease.
* Smoking, alcohol consumption \> 2 servings /d for males and 1 serving/d for females, or taking medications (including but not limited to statins or other drugs with anti-inflammatory actions) or antioxidant vitamins or supplements.
* Known allergy, hypersensitivity, or intolerance to inulin.
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kevin Davy

Kevin P. Davy, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kevin P Davy, PhD

Role: PRINCIPAL_INVESTIGATOR

Virginia Polytechnic and State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Virginia Polytechnic and State University

Blacksburg, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Prebiotics-Prediabetes

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Fiber on Glycemic Index
NCT02615327 COMPLETED NA
Fiber Mix and Glycemic Response
NCT03334643 COMPLETED NA